RGD delivery of truncated coagulase to tumor vasculature affords local thrombotic activity to induce infarction of tumors in mice

• Published in: Scientific reports 2017-08, Vol.7 (1), p.8126-14, Article 8126
• Main Authors: Jahanban-Esfahlan, Rana, Seidi, Khaled, Monhemi, Hassan, Adli, Amir Daei Farshchi, Minofar, Babak, Zare, Peyman, Farajzadeh, Davoud, Farajnia, Safar, Behzadi, Ramezan, Abbasi, Mehran Mesgari, Zarghami, Nosratollah, Javaheri, Tahereh
• Format: Article
• Language: English
• Subjects: 13; 13/31; 14/34; 59; 631/114/2410; 631/1647/2230/2233; 631/535/1267; 631/67/1059/153; 631/92/152; 64/110; 82/16; 82/29; 82/80; 82/83; Animals; Bacterial Proteins - genetics; Bacterial Proteins - metabolism; C-Terminus; Cancer; Cell Line, Tumor; Cells, Cultured; Coagulase; Coagulase - genetics; Coagulase - metabolism; Colon; Endothelial cells; Fusion protein; Genetic engineering; Growth inhibition; Humanities and Social Sciences; Humans; Infarction; Infarction - pathology; Mice, Inbred C57BL; Mice, Nude; multidisciplinary; Mutation; Neoplasms - genetics; Neoplasms - metabolism; Neoplasms - therapy; Neovascularization, Pathologic - genetics; Neovascularization, Pathologic - metabolism; Neovascularization, Pathologic - pathology; Oligopeptides - genetics; Ovarian cancer; Prothrombin; Recombinant Fusion Proteins - genetics; Recombinant Fusion Proteins - metabolism; Science; Science (multidisciplinary); Solid tumors; Thromboembolism; Thrombosis; Thrombosis - genetics; Thrombosis - metabolism; Tumor Burden - genetics; Tumors; Xenograft Model Antitumor Assays - methods
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-017-05326-9

Induction of thrombosis in tumor vasculature represents an appealing strategy for combating cancer. Herein, we combined unique intrinsic coagulation properties of staphylocoagulase with new acquired functional potentials introduced by genetic engineering, to generate a novel bi-functional fusion protein consisting of truncated coagulase (tCoa) bearing an RGD motif on its C-terminus for cancer therapy. We demonstrated that free coagulase failed to elicit any significant thrombotic activity. Conversely, RGD delivery of coagulase retained coagulase activity and afforded favorable interaction of fusion proteins with prothrombin and α v β 3 endothelial cell receptors, as verified by in silico, in vitro , and in vivo experiments. Although free coagulase elicited robust coagulase activity in vitro , only targeted coagulase (tCoa-RGD) was capable of producing extensive thrombosis, and subsequent infarction and massive necrosis of CT26 mouse colon, 4T1 mouse mammary and SKOV3 human ovarian tumors in mice. Additionally, systemic injections of lower doses of tCoa-RGD produced striking tumor growth inhibition of CT26, 4T1 and SKOV3 solid tumors in animals. Altogether, the nontoxic nature, unique shortcut mechanism, minimal effective dose, wide therapeutic window, efficient induction of thrombosis, local effects and susceptibility of human blood to coagulase suggest tCoa-RGD fusion proteins as a novel and promising anticancer therapy for human trials.